Guidelines and Quality Measures. Do They Improve Outcomes of Patients with Community-Acquired Pneumonia?

Infectious Disease Clinics of North America

Volumn 27, Issue 1, 2013, Pages 71-86

  Johnstone, Jennie ^a,b   Mandell, Lionel ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Community acquired pneumonia; Guidelines; Outcome measures; Pay for performance; Quality indicators; Quality measures

Indexed keywords

ANTIBIOTIC AGENT; INFLUENZA VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE;

ACTIVE IMMUNIZATION; BLOOD CULTURE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; DRUG EFFICACY; HEALTH CARE COST; HEALTH CARE QUALITY; HOSPITAL CARE; HOSPITAL READMISSION; HUMAN; INFLUENZA; INFLUENZA VACCINATION; LENGTH OF STAY; MANAGED CARE; MORTALITY; OUTCOME ASSESSMENT; OUTPATIENT CARE; OXYGEN BLOOD LEVEL; PNEUMOCOCCAL INFECTION; PRACTICE GUIDELINE; RESPIRATORY CARE; REVIEW; SMOKING CESSATION; TOTAL QUALITY MANAGEMENT;

EID: 84873531706     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2012.11.001     Document Type: Review

References (73)

1. Brar N.K., Niederman M.S. Management of community-acquired pneumonia: a review and update. Ther Adv Respir Dis 2011, 5(1):61-78.
2. Jackson M.L., Neuzil K.M., Thompson W.W., et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004, 39:1642-1650.
3. Nazarian D., Eddy O.L., Lukens T.W., et al. Clinical policy: critical issues in the management of adult patients presenting to the emergency department with community-acquired pneumonia. Ann Emerg Med 2005, 54(5):704-731.
4. European Respiratory Society Pneumonia. European lung white book. Lausane 2003, 55-65. European Respiratory Society. R. Loddenhempe (Ed.).
5. Gleason P.P., Kapoor W.N., Stone R.A., et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA 1997, 278:32-39.
6. Suchyta M.R., Dean N.C., Narus S., et al. Effects of a practice guideline for community-acquired pneumonia in an outpatient setting. Am J Med 2001, 110:306-309.
7. Niederman M.S., Bass J.B., Campbell G.D., et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 1993, 148:1418-1426.
8. Bjerre L.M., Verheij T.J., Kochen M.M. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database Syst Rev 2009, (4). CD002109.
9. Dean N.C., Silver M.P., Bateman K.A., et al. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 2001, 110:451-457.
10. Musher D.M., Rueda A.M., Kaka A.S., et al. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 2007, 45(2):158-165.
11. Dudas V., Hopefl A., Jacobs R., et al. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of non-teaching US community hospitals. Ann Pharmacother 2000, 34:446-452.
12. Menendez R., Ferrando D., Valles J.M., et al. Influence of deviation from guidelines on the outcome of community-acquired pneumonia. Chest 2002, 122:612-617.
13. Capelastegui A., Espana P.P., Quintana J.M., et al. Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. Clin Infect Dis 2004, 39:955-963.
14. Frei C.R., Restrepo M.I., Mortensen E.M., et al. Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia. Am J Med 2006, 119:865-871.
15. Dean N.C., Bateman K.A., Donnelly S.M., et al. Improved clinical outcomes with utilization of a community-acquired pneumonia guideline. Chest 2006, 130:794-799.
16. Mortensen E.M., Restrepo M.I., Anzueto A., et al. Antibiotic therapy and 48-hour mortality for patients with pneumonia. Am J Med 2006, 119:859-864.
17. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low risk patients with community-acquired pneumonia. N Engl J Med 1997, 336(4):243-250.
18. Calzada R.S., Martinez Tomas R., Cremades Romero M.J., et al. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission. Respir Med 2007, 101(9):1909-1915.
19. Garau J., Baquero F., Perez-Trallero E., et al. Factors impacting on length of stay and mortality of community-acquired pneumonia. Clin Microbiol Infect 2008, 14:322-329.
20. Arnold F.W., Summersgill J.T., Lajoie A.S., Community-Acquired Pneumonia Organization (CAPO) Investigators, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007, 175(10):1086-1093.
21. Mandell L.A., Marrie T.J., Grossman R.F., et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000, 31(2):383-421.
22. Yanagihara K., Kohno S., Matsusima T. Japanese guidelines for the management of community-acquired pneumonia. Int J Antimicrob Agents 2001, 18(Suppl 1):S45-S48. [review].
23. Vogel F., Worth H., Adam D., et al. Chemotherapie Journal 2000, 1:3-23. For the Paul Ehrlich Society for Chemotherapy and the German Respiratory Association, [in German].
24. Menendez R., Reyes S., Martinez R., et al. Economic evaluation of adherence to treatment guidelines in non-intensive care pneumonia. Eur Respir J 2007, 29:751-756.
25. Blasi F., Iori I., Bulfoni A., et al. Can CAP guideline adherence improve patient outcome in internal medicine departments?. Eur Respir J 2008, 32:902-910.
26. Mandell L.A., Wunderink R.G., Anzueto A., et al. IDSA/ATS consensus guidelines on the management of community-acquired pneumonia. Clin Infect Dis 2007, 44:S27-S72.
27. McCabe C., Kirchner C., Zhang H., et al. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. Arch Intern Med 2009, 169(16):1525-1531.
28. Stahl J.E., Barza M., DesJardin J., et al. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999, 159:2576-2580.
29. Gora-Harper M.L., Rapp R.P., Finney J.P. Development of a best-practice model at a university hospital to increase efficiency in the management of patients with community-acquired pneumonia. Am J Health Syst Pharm 2000, 57(Suppl 3):S6-S9.
30. Bartlett J.G., Breiman R.F., Mandell L.A., et al. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis 1998, 26(4):811-838.
31. Marrie T.J., Lau C.Y., Wheeler S.L., et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. Capital Study Investigators. Community-acquired pneumonia intervention trial assessing levofloxacin. JAMA 2000, 283:749-755.
32. Meehan T.P., Weingarten S.R., Holmboe E.S., et al. A statewide initiative to improve the care of hospitalized pneumonia patients: the Connecticut Pneumonia Pathway Project. Am J Med 2001, 111:203-210.
33. Battleman D.S., Callahan M., Thaler H.T. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization. Arch Intern Med 2002, 162:682-688.
34. Orrick J.J., Segal R., Johns T.E., et al. Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to Infectious Diseases Society of America guidelines. Pharmacoeconomics 2004, 22:751-757.
35. Niederman M.S., Mandell L.A., Anzueto A., et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. American Thoracic Society. Am J Respir Crit Care Med 2001, 163(7):1730-1754.
36. Mandell L.A., Bartlett J.G., Dowell S.F., et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Infectious Diseases Society of America. Clin Infect Dis 2003, 37(11):1405-1433.
37. Dambrava P.G., Torres A., Valles X., et al. Adherence to guidelines' empirical antibiotic recommendations and community-acquired pneumonia outcome. Eur Respir J 2008, 32:892-901.
38. Menendez R., Torres A., Rodriguez de Castro F., et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004, 39:1783-1790.
39. Marrie T.J., Shariatzadeh M.R. Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study. Medicine (Baltimore) 2007, 86:103-111.
40. Riley P.D., Aronsky D., Dean N.C. Validation of the 2001 American Thoracic Society criteria for severe community-acquired pneumonia. Crit Care Med 2004, 32:2398-2402.
41. Woodhead M.A., Macfarlane J.T., Rodgers F.G., et al. Aetiology and outcome of severe community-acquired pneumonia. J Infect 1985, 10:204-210.
42. Leroy O., Saux P., Bedos J.P., et al. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005, 128:172-183.
43. Rello J. Demographics, guidelines, and clinical experience in severe community-acquired pneumonia. Crit Care 2008, 12(Suppl 6):S2.
44. Bodí M., Rodríguez A., Solé-Violán J., et al. Community-acquired pneumonia intensive care units (CAPUCI) study investigators. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis 2005, 41(12):1709-1716.
45. Shorr A.F., Bodi M., Rodriguez A., CAPUCI Study Investigators, et al. Impact of antibiotic guideline compliance on duration of mechanical ventilation in critically ill patients with community-acquired pneumonia. Chest 2006, 130(1):93-100.
46. Martin-Loeches I., Lisboa T., Rodriguez A., et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010, 36(4):612-620.
47. Frei C.R., Attridge R.T., Mortensen E.M., et al. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit. Clin Ther 2010, 32(2):293-299.
48. Wu J., Howard D., McGowan J., et al. Adherence to Infectious Diseases Society of America guidelines for empiric therapy for patients with community acquired pneumonia in a commercially insured cohort. Clin Ther 2006, 28:141-1461.
49. Menendez R., Torres A., Zalacain R., et al. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med 2005, 172:757-762.
50. Centers for Medicare and Medicaid Services, the Joint Commission. Specification manual for national hospital quality measures. Available at: . Accessed August 31, 2012. http://www.jointcommission.org/specifications_manual_for_national_hospital_inpatient_quality_measures.aspx.
51. Feikin D.R., Schuchat A., Kolczak M., et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000, 90(2):223-229.
52. Centers for Disease Control and Prevention Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010, 59(34):1102-1106.
53. Pneumococcal vaccination. Public Health Agency of Canada. Canadian immunization guide 2006, 267-276. Public Health Agency of Canada, Ottawa (Canada). 7th edition.
54. Wilson K., Schunemann H. An appraisal of the evidence underlying performance measures for community acquired pneumonia. Am J Respir Crit Care Med 2011, 183:1454-1462.
55. Andrews R., Moberley A. The controversy over the efficacy of pneumococcal vaccine. CMAJ 2009, 180:18-19.
56. Moberley S., Holden J., Tatham D.P., et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008, (1). CD000422.
57. Centers for Disease Control and Prevention Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR Morb Mortal Wkly Rep 2012, 61:394-395.
58. Hak E., Grobbee D.E., Sanders E.A., et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008, 66(9):378-383.
59. Nuorti J., Butler J., Farley M., et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000, 342:681-689.
60. Rigotti N., Clair C., Munafo M., et al. Interventions for smoking cessation in hospitalized patients. Cochrane Database Syst Rev 2012, (5). CD001837.
61. Dedier J., Singer D., Chang Y., et al. Processes of care, illness severity, and outcomes in the management of community-acquired pneumonia at academic hospitals. Arch Intern Med 2001, 161:2099-2104.
62. Meehan T., Fine M., Krumholz H., et al. Quality of care process and outcomes in elderly patients with pneumonia. JAMA 1997, 278:2080-2084.
63. Houck P., Bratzler D., Nsa W., et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004, 164:637-644.
64. Falsey A.R., Walsh E.E. Viral pneumonia in older adults. Clin Infect Dis 2006, 42:518-524.
65. Jefferson T., Di Pietrantonj C., Al-Ansary L.A., et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010, (2). CD004876.
66. Jefferson T., Di Pietrantonj C., Rivetti A., et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010, (7). CD001269.
67. Govaert T.M., Thijs C.T., Masurel N., et al. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994, 272:1661-1665.
68. Fulop T., Pawelec G., Castle S., et al. Immunosenescence and vaccination in nursing home residents. Clin Infect Dis 2009, 48:443-448.
69. Shorr A., Owens R. Guidelines and quality for community-acquired pneumonia: measures from the Joint Commission and the Centers for Medicare and Medicaid Services. Am J Health Syst Pharm 2009, 66:S2-S7.
70. Jha A., Joynt K., Orav J., et al. The long-term effect of premier pay for performance on patient outcomes. N Engl J Med 2012, 366:1606-1615.
71. Lindenauer P., Remus D., Roman S., et al. Public reporting and pay for performance in hospital quality improvement. N Engl J Med 2007, 356:486-496.
72. Werner R., Kolstad J., Stuart E., et al. The effect of pay-for-performance in hospitals: lessons for quality improvement. Health Aff (Millwood) 2011, 30:690-698.
73. Asadi L., Sligl W.I., Eurich D.T., et al. Macrolide based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2012, 55(3):371-378.